Shots:

• The OPTION study involves assessing of Watchman FLX left atrial appendage closure vs oral anticoagulants (OAC) including direct oral anticoagulants (DOAC) & warfarin in 1-600 patients with non-valvular AF who undergo a cardiac ablation across 130 sites globally
• The OPTION study will have its 1EPs as all cause death- stroke and systemic embolism with primary safety endpoint as non-procedural bleeding @ 36mos.
• The WATCHMAN FLX is a device- designed for simplified implantation- enhancing sealing within the left atrial appendage- and offer physicians to recapture and reposition the device during the procedure and has received CE Mark in Mar’19

Ref: Boston Scientific | Image: Verdict Medical Devices